Key Insights

Highlights

Success Rate

81% trial completion

Published Results

47 trials with published results (40%)

Research Maturity

68 completed trials (58% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

13.6%

16 terminated out of 118 trials

Success Rate

81.0%

-5.6% vs benchmark

Late-Stage Pipeline

3%

4 trials in Phase 3/4

Results Transparency

69%

47 of 68 completed with results

Key Signals

47 with results81% success16 terminated

Data Visualizations

Phase Distribution

113Total
Not Applicable (17)
Early P 1 (1)
P 1 (30)
P 2 (61)
P 3 (4)

Trial Status

Completed68
Terminated16
Recruiting10
Unknown9
Active Not Recruiting6
Withdrawn5

Trial Success Rate

81.0%

Benchmark: 86.5%

Based on 68 completed trials

Clinical Trials (118)

Showing 20 of 20 trials
NCT07686380Phase 2Not Yet RecruitingPrimary

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

NCT06096870Phase 2Recruiting

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

NCT06378866Phase 2Recruiting

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

NCT03718260Not ApplicableCompletedPrimary

PSMA-PET Registry for Recurrent Prostate Cancer

NCT07365423Phase 2RecruitingPrimary

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

NCT07593079Phase 2Not Yet Recruiting

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT03246802Not ApplicableRecruitingPrimary

Partial Prostate Salvage High Dose Rate Brachytherapy

NCT02217709Phase 2Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

NCT01802346Not ApplicableActive Not Recruiting

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT05304858RecruitingPrimary

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

NCT04019964Phase 2Completed

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

NCT03067051Phase 1RecruitingPrimary

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

NCT04787744Phase 2Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT03496805Phase 2CompletedPrimary

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

NCT07090148Phase 1Recruiting

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

NCT03495427Phase 2Recruiting

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT05746806Not ApplicableActive Not RecruitingPrimary

Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy

NCT07290998Not ApplicableNot Yet Recruiting

Treatment of Locally Recurrent Prostate Cancer

NCT01923506Phase 1Active Not RecruitingPrimary

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

NCT02023463Phase 1Active Not Recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Scroll to load more

Research Network

Activity Timeline